Fas/FasL interaction: A novel immune therapy approach with immobilized biologicals

✍ Scribed by Martin Scholz; Jindrich Cinatl

• Book ID: 102506263
• Publisher: John Wiley and Sons
• Year: 2005
• Tongue: English
• Weight: 322 KB
• Volume: 25
• Category: Article
• ISSN: 0198-6325
• DOI: 10.1002/med.20025

✦ Synopsis

Systemically applied agents to modulate the Fas/FasL system, e.g., by stimulation of Fas on activated leukocytes or tumor cells failed as strategies in immune therapy due to severe toxic effects in the host. Recently, a novel strategy has been developed by using immobilized immune active biologicals in a medical device that may allow immune management without expensive systemic therapy. This review reports on the potential role of Fas/FasL in immune therapy and summarizes current experimental and clinical data with the leukocyte inhibition module (LIM), an immobilized anti-Fas antibody containing device yet used in extracorporeal blood circulation. This proof of principal may stimulate the development of other devices based on the regulation of Fas/FasL or other targets relevant for immune disorders.